Table 2. Effects of probiotics in clinical trials on patients with AD.
References | Probiotics strain/s | Clinical patients | Observations | Clinical outcome (SCORAD index, clinical symptoms) |
---|---|---|---|---|
Navarro-López et al.31 | Bifidobacterium lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lactobacillus casei CECT 9104 | Pediatric | Reduced use of topical corticosteroids | Improved |
Wang et al.30 | Lactobacillus paracasei, Lactobacillus fermentum and mixture | Pediatric | Reduced IL-4, marginally increased TGF-β, IFN-γI | Improved |
Niccoli et al.63 | Lactobacillus salivarius LS01 | Pediatric | - | Improved |
Yang et al.64 | Mix: L. casei, Lactobacillus rhamnosus, Lactobacillus plantarum, and B. lactis | Pediatric | No change in cytokine profile | No change from placebo |
Inoue et al.65 | Heat killed Lactobacillus acidophilus strain L-92 | Pediatric | Reduced eosinophil count, increased TGF-β | Improved |
Wickens et al.35 | L. rhamnosus HN001 | Pediatric | Reduced serum total IgE, | Improved |
Yeşilova et al.66 | Mix: Bifidobacterium bifidum, L. acidophilus, L. casei, and L. salivarius | Pediatric | Reduced IL-5, IL-6, IFN-γ and total serum IgE | Improved |
Iemoli et al.67 | Mix L. salivarius LS01 and Bifidobacterium breve BR03 | Adults | Reduced Th1/Th2 cytokines and Th17/Treg ratio | Improved |
Han et al.29 | L. plantarum CJLP133 | Pediatric | Reduced IL-4, IFN-γ and total eosinophil count | Improved |
Gore et al.68 | L. paracasei CNCM I-2116 or B. lactis CNCM I-3446 | Pediatric | - | No change from placebo |
Drago et al.69 | L. salivarius LS01 | Adults | Reduced Th1 cytokines (IL-12, IFN-γ), Th1/Th2 cytokines ratio and serum IgE | Improved |
Woo et al.70 | Lactobacillus sakei KCTC 10755BP | Pediatric | Lower serum levels of CCL17 and CCL27 | Improved |
AD, atopic dermatitis; SCORAD, Scoring Atopic Dermatitis; IL, interleukin; TGF, transforming growth factor; IFN, interferon; IgE, immunoglobulin E; Th2, type 2 helper T cell; Th1, type 1 helper T cell; Treg, regulatory T cell.